Physician profile
Robert John Young
NPI 1427643386
$2,620.99
in general payments reported to CMS, 2019-2025
14 companies · $36.65 in 2025
The $36.65 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $732 · 2022: $526 · 2023: $849 · 2024: $478 · 2025: $36.65.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,364.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,363.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $614.13 | 2021-2024 | Ztlido |
| Collegium Pharmaceutical, INC. | $520.12 | 2021-2024 | Belbuca, Xtampza, Nucynta |
| Forte Bio-Pharma LLC | $296.56 | 2021-2024 | Prolate, Nalocet |
| Braeburn INC. | $269.14 | 2023-2024 | Brixadi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $222.62 | 2021-2024 | Relistor |
| Indivior INC. | $176.95 | 2021-2024 | Sublocade |
| Almatica Pharma LLC | $95.97 | 2021 | |
| Idorsia Pharmaceuticals US INC | $75.18 | 2023 | Quviviq |
| Redhill Biopharma INC. | $72.97 | 2021 | |
| Abbvie INC. | $71.58 | 2021-2022 | |
| Virtus Pharmaceuticals LLC | $66.53 | 2023-2025 | Levorphanol Tartrate |
| Valinor Pharma, LLC | $60.49 | 2024-2025 | Movantik |
| Biodelivery Sciences International, INC. | $52.32 | 2021 | |
| Arbor Pharmaceuticals, INC. | $26.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.